Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nanomilled testosterone · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Nanomilled testosterone | DRUG | - |
| Nanomilled dutasteride | DRUG | - |
| commercially available dutasteride | DRUG | - |
Inclusion criteria: * Have a diagnosis of primary or secondary hypogonadism. * Have very low testosterone levels on 2 separate days. * Have a BMI within range of 18.5-35kg/m2. * Have not taken dutasteride for one year, or finasteride for the past 3 months. Exclusion criteria: * Have had or have b...
Nanomilled testosterone is an investigational small molecule being developed for hypogonadism, a condition in which the body does not produce enough testosterone. It is in Phase 2 clinical development and is not yet approved by the FDA.
Nanomilled testosterone is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 2 clinical trials for hypogonadism.
Nanomilled testosterone is in Phase 2 clinical development for hypogonadism. It is an investigational drug and has not been approved by regulatory authorities. Two clinical trials have been completed, including one Phase 2 study.
Nanomilled testosterone has been studied in two completed clinical trials. NCT00398580 was a 28-day Phase 2 study in hypogonadal men, and NCT00400335 was a Phase 1 study on bioavailability and pharmacokinetics. Both trials were conducted in the United States.
Nanomilled testosterone is a form of testosterone that has been nanomilled, a process that reduces particle size to improve absorption. It is being studied for hypogonadism, and in clinical trials it has been administered with and without dutasteride.